September 6, 2021
Janssen Pharmaceutical’s Darzquro (daratumumab + vorhyaluronidase alfa), which was approved late last month for an additional indication of systemic light-chain (AL) amyloidosis, is expected to treat up to roughly 900 patients every year, a specialist says. An estimated 3,200 people...read more